Drugs / EPIGALOCATECHIN GALLATE
EPIGALOCATECHIN GALLATE
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00434499 Comparator | Feb 2007 → Dec 2015 | hypertensive disorder, obesity disorder, type 2 diabetes mellitus | University of Maryland, Baltimore | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPIGALOCATECHIN GALLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL297453 ↗ |
| Known as | EGCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00434499 ↗ |
| Known as | epigallocatechin 3-gallate | “the bioactive polyphenol epigallocatechin 3-gallate (EGCG)” NCT00434499 ↗ |
| Known as | epigallocatechin gallate | “epigallocatechin gallate (EGCG), a major component of green tea” NCT00434499 ↗ |
| Modality | Small molecule | — CHEMBL297453 ↗ |
| Route | Oral | “oral EGCG administration” NCT00434499 ↗ |